Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma

NCT07643519 is registered in ClinicalTrials.gov with University of Florida as lead sponsor.

NCT NCT07643519
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07643519 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma
Lead sponsor
University of Florida
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
October 31, 2030
Enrollment
39 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial carcinoma (uc)